LBA4 Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma
Titel:
LBA4 Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma
Auteur:
Al-Batran, S-E. Wainberg, Z.A. Muro, K. Molena, D. Van Cutsem, E. Hyung, W.J. Wyrwicz, L.S. Moehler, M. Herrero, F. Rivera Oh, D-Y. Omori, T. Smyth, E.C. Liberman, M. Stein, A. Bilici, M. Serrano, O. Heilbron, E. Hernandorena, F. Tabernero, J. Janjigian, Y.Y.